Interferon Beta-1A

證據等級: L5

預測適應症: 10 個

Interferon beta-1a: From Multiple Sclerosis to Jeune Syndrome Situs Inversus

One-Sentence Summary

Interferon beta-1a (IFN β-1a) is a recombinant cytokine biologic widely established for the treatment of relapsing-remitting multiple sclerosis (MS) — though no original indication is formally registered in India’s regulatory database. The TxGNN model ranks Jeune syndrome situs inversus as the top predicted new indication, with a score of 97.47%. However, no clinical trials and no relevant literature exist to support this prediction — the high score is assessed as a knowledge graph topology artifact, not a clinically actionable signal.

Quick Overview

Item	Content
Original Indication	Not registered in India (no approved licenses on record; known globally for relapsing-remitting MS)
Predicted New Indication	Jeune Syndrome Situs Inversus
TxGNN Prediction Score	97.47%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, no detailed mechanism of action data is available in this Evidence Pack. Based on widely published pharmacology, Interferon beta-1a binds to the heterodimeric IFNAR1/IFNAR2 receptor complex on cell surfaces, activating the JAK1/TYK2 → STAT1/STAT2 → ISGF3 signalling cascade, which drives transcription of interferon-stimulated genes (ISGs). This pathway modulates innate and adaptive immunity — suppressing pro-inflammatory T-cell activity, reducing lymphocyte trafficking across the blood-brain barrier, and upregulating anti-inflammatory cytokines. Its clinical benefit in MS is rooted in immune dysregulation correction, not in structural tissue repair.

Jeune syndrome (asphyxiating thoracic dystrophy) with situs inversus is a ciliopathy — a congenital defect of primary cilia function — manifesting as skeletal dysplasia, restricted thoracic cage development, and, in some cases, situs inversus totalis due to defective cilia-driven left-right patterning in embryogenesis. This is a fixed structural malformation established before birth. The IFN β-1a immune-modulatory pathway has no known mechanism to correct or compensate for germline ciliopathy defects or to reverse situs inversus anatomy.

The TxGNN knowledge graph likely assigns a high score here because ciliary biology nodes (e.g., IFT genes, DNAI1) and immune regulation nodes share indirect edges in the graph topology — a structural artifact rather than a biologically meaningful therapeutic connection. All 10 top-ranked predictions in this Evidence Pack are congenital structural or chromosomal disorders, reinforcing the interpretation that these are systematic graph topology false signals for IFN β-1a, not genuine repurposing opportunities.

Clinical Trial Evidence

Currently no related clinical trials registered for Interferon beta-1a in Jeune syndrome situs inversus.

Literature Evidence

Currently no related literature available for Interferon beta-1a in Jeune syndrome situs inversus.

Note on apparent literature count: The evidence pipeline retrieved 20 publications under the “disorder of fucoglycosan synthesis” query (rank #4). These have been reviewed and confirmed as false positives — all articles address IFN β-1a in multiple sclerosis, COVID-19, COPD, and ARDS, with zero semantic relevance to fucoglycosan metabolism or the ciliopathy spectrum that includes Jeune syndrome. They are not counted as supporting evidence for any indication in this report.

India Market Information

Interferon beta-1a has no registered products in India’s drug regulatory database. No authorization numbers, brand names, dosage forms, or approved indications are on record.

Safety Considerations

Drug Interactions: A total of 284 drug-drug interactions have been identified (DDInter database). Clinically notable interactions include:

Major severity: Bupropion — risk of increased adverse effects; combination requires careful clinical assessment
Moderate severity (selected): Rosuvastatin, Simvastatin (hepatotoxicity monitoring recommended); Clarithromycin, Levofloxacin, Minocycline (immunomodulatory overlap); Pioglitazone, Rosiglitazone, Acarbose (glucose metabolism effects in diabetic patients); Naltrexone; Orlistat; Anabolic steroids (Oxandrolone, Oxymetholone, Stanozolol — hepatotoxicity risk)

For complete warnings and contraindications, please refer to the approved package insert (SmPC/Prescribing Information). Formal TFDA labelling data was not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial evidence, no disease-relevant literature, and no mechanistic plausibility linking IFN β-1a to Jeune syndrome situs inversus. The TxGNN high score reflects a knowledge graph topology artifact — indirect cilia/immune node proximity — rather than a translatable therapeutic hypothesis. Additionally, IFN β-1a is not marketed in India, further limiting any near-term repurposing pathway.

To proceed with any future evaluation of this drug, the following is needed:

Obtain the official prescribing information / SmPC for IFN β-1a (Avonex, Rebif, or equivalent) to fill the MOA and safety data gaps
Run a targeted literature review across all ranked indications to identify whether any L3–L4 level mechanistic evidence exists (e.g., IFN pathway involvement in ciliopathies)
Reassess whether TxGNN graph embeddings for IFN β-1a are over-indexing on immune/structural node co-occurrence — a calibration review of the knowledge graph edges is recommended before generating further candidates for this drug
If repurposing is still of interest, pivot to indications where IFN β-1a has established biological rationale: autoimmune disorders, viral infections (COVID-19, COPD viral exacerbations), or neurodegenerative conditions with inflammatory components
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.